337(top 1%)
papers
16.5K(top 1%)
citations
63(top 1%)
h-index
125(top 0.1%)
g-index
384
all documents
19.5K
doc citations
2.7K
citing journals

Top Articles

#TitleJournalYearCitations
1CD8+ T cells regulate tumour ferroptosis during cancer immunotherapyNature20191,528
2Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019943
3Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020848
4Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019700
5Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019672
6Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11Cancer Discovery2019566
7Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2022562
8Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell eliminationNature Medicine2021451
9NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018Journal of the National Comprehensive Cancer Network: JNCCN2018394
10Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019393
11Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019385
12Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020383
13Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialLancet Oncology, The2020330
14Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working GroupJournal of the National Cancer Institute2021319
15Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019314
16NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Journal of the National Comprehensive Cancer Network: JNCCN2020314
17Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2019298
18NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020Journal of the National Comprehensive Cancer Network: JNCCN2020284
19Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019Journal of the National Comprehensive Cancer Network: JNCCN2019281
20Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic CancerCell Metabolism2019280
21Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumAnnals of Oncology2021240
22Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2018202
23NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019Journal of the National Comprehensive Cancer Network: JNCCN2019200
24Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialLancet Haematology,the2019194
25Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket studyLancet Oncology, The2020194
26NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018Journal of the National Comprehensive Cancer Network: JNCCN2018192
27NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019Journal of the National Comprehensive Cancer Network: JNCCN2019191
28NCCN Guidelines Insights: Kidney Cancer, Version 2.2020Journal of the National Comprehensive Cancer Network: JNCCN2019185
29Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphomaBlood2019184
30NCCN Guidelines Insights: Bladder Cancer, Version 5.2018Journal of the National Comprehensive Cancer Network: JNCCN2018171
31NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022Journal of the National Comprehensive Cancer Network: JNCCN2022169
32NCCN Guidelines Insights: Kidney Cancer, Version 1.2021Journal of the National Comprehensive Cancer Network: JNCCN2020163
33Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade TherapyCancer Research2019154
34Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19JAMA Oncology2021149
35Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020147
36Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialLancet Oncology, The2022147
37Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline UpdateJournal of Clinical Oncology2022139
38Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2022124
39NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019Journal of the National Comprehensive Cancer Network: JNCCN2019116
40Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite VaccineClinical Cancer Research2018114
41Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2018113
42NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021Journal of the National Comprehensive Cancer Network: JNCCN2021113
43NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020Journal of the National Comprehensive Cancer Network: JNCCN2019113
44Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapyJournal of Clinical Investigation2020112
45O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3Immunity2019111
46HPV16 drives cancer immune escape via NLRX1-mediated degradation of STINGJournal of Clinical Investigation2020104
47HER2 and Breast Cancer — A Phenomenal Success StoryNew England Journal of Medicine2019102
48Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network: JNCCN2020102
49NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021Journal of the National Comprehensive Cancer Network: JNCCN202198
50Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJournal of Clinical Oncology202197